碘丰富地区放射性碘治疗格雷夫斯病前预先给予碘化钾及不同时长低碘饮食对疗效的影响
该回顾性研究纳入爱知县114例与北海道71例共185例格雷夫斯甲亢患者,按抗甲状腺药物或碘化钾预处理及低碘饮食18天(A组)或7天(H组)分组,调整131I剂量使甲状腺吸收剂量>100 Gy。结果显示低碘饮食可显著降低尿碘浓度,但尿碘浓度与1年治疗成功率无显著关联,A组与H组成功率分别为85%与89%。
要点
- 低碘饮食可显著降低格雷夫斯甲亢患者放射性碘治疗前的尿碘浓度(P<0.01)。
- A组与H组1年放射性碘治疗成功率分别为85%与89%。
- 尿碘浓度与24小时摄碘率呈负相关但差异不显著,与治疗成功率无显著关联。
核心结论
- 低碘饮食足以降低接受放射性碘治疗患者的尿碘浓度,但尿碘浓度降低未提高治疗成功率,低碘饮食增强格雷夫斯甲亢放射性碘疗效的获益仍不确定。
研究设计与样本
- 回顾性评估185例格雷夫斯甲亢患者,来自爱知县(n=114)与北海道(n=71),年龄≥18岁,于2012年12月至2022年3月间接受放射性碘治疗。
- 按抗甲状腺药物或碘化钾预处理分为亚组,低碘饮食从放射性碘治疗前18天(A组)或7天(H组)持续至治疗后3天。
- 调整131I剂量使甲状腺吸收剂量>100 Gy,比较尿碘浓度与24小时摄碘率及1年治疗成功率的关系。
主要发现
- 与UIC1相比,所有亚组UIC2均显著降低(P<0.01)。
- 四个组中UIC2与24小时摄碘率呈负相关,但差异不显著。
- A组与H组1年治疗成功率分别为85%与89%。
- 单因素分析显示各组中UIC2与治疗成功率均无关联,按UIC2四分位分层185例患者治疗成功率无显著差异(p=0.79)。
关键数值与推荐
- 131I剂量调整至使甲状腺吸收剂量>100 Gy。
- 低碘饮食持续时间:A组从治疗前18天至治疗后3天,H组从治疗前7天至治疗后3天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine whether adherence to a low-iodine diet (LID) enhances the therapeutic efficacy of radioiodine therapy (RAI) in Graves' hyperthyroidism (GH) in iodine-rich areas. METHODS: We retrospectively evaluated 185 patients with GH from Aichi (n = 114) and Hokkaido (n = 71) Prefectures. Patients aged ≥ 18 years with GH who underwent RAI between December 2012 and March 2022 were divided into subgroups based on pretreatment with anti-thyroid drug (ATD) or potassium iodide (KI). Patients were followed up with LID from 18 days (group A) or 7 days (group H) before RAI to 3 days after RAI. The dose of radioactive iodine 131 (131I) was adjusted to deliver > 100 Gy to the thyroid. The associations between urinary iodine concentration on UIC2 vs. 24hRU and UIC2 vs. the 1-year RAI success rate (SR) were investigated. RESULTS: Compared with UIC1, UIC2 was significantly decreased in all subgroups (P < 0.01). An inverse correlation between UIC2 and 24hRU was observed in the four groups; however, the difference was insignificant. The SR in groups A and H was 85% and 89%, respectively. Univariate analysis revealed no association between UIC2 and SR in each group. Additionally, stratification of the 185 patients into quartiles using UIC2 yielded no significant differences in SR (p = 0.79). CONCLUSIONS: LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.
引用
- Tamura M, Nakada K, Iwanaga H, et al. Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas. Eur J Nucl Med Mol Imaging. 2023. PMID: 38008728. doi:10.1007/s00259-023-06523-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。